MedTrace Logo

Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis

NCT00043329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2007-11-01

No results posted yet for this study

Summary

The purpose of this study is to establish a registry of all children with severe, malignant osteopetrosis who are treated with Actimmune (IFN-g 1b or Interferon gamma-1b) to monitor the effects of IFN-g 1b on preventing progression of this disease and to follow the safety of patients receiving it on a long-term basis. In addition, evaluation of the possible effect of Actimmune therapy on the humoral response to normal childhood vaccinations in this same patient population will be examined.Interferon gamma is a substance that the body makes naturally.

Conditions

  • Osteopetrosis

Interventions

DRUG

Actimmune Registry

as administered by physician

Sponsors & Collaborators

  • InterMune

    lead INDUSTRY

Principal Investigators

  • Steven Porter, MD · InterMune

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00043329 on ClinicalTrials.gov